Lamivudine for hepatitis B in clinical practice

Journal of Medical Virology

Volumn 61, Issue 3, 2000, Pages 386-391

  Schiff, Eugene R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hepatitis B; Nucleoside analogue; Safety; Treatment; YMDD variant

Indexed keywords

LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; LIVER TOXICITY; NONHUMAN; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER; TREATMENT OUTCOME; VIRUS REPLICATION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0034040935     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200007)61:3<386::AID-JMV18>3.0.CO;2-X     Document Type: Article

References (37)

1. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, Lai CL, Dusheiko G, Dienstag J, Wright T, Barnard J, Bourne E, Condreay L. 1998. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 28:319A (Abstract 625).
2. Boag F. 1991. Hepatitis B: heterosexual transmission and vaccination strategies. Int J Std AIDS 2:318-324.
3. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968-975.
4. Chang TT, Lai CL, Liaw YF, Leung NWY, Guan R, Lim SG, Lee CM, Ng KY, Edmundson S, Stevenson C, Dent JC. 1999. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine. Hepatology 30:421A.
5. Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, Rubin M, Brown N, and the US Lamivudine Investigator Group. 1998. Lamivudine treatment for one year in previously untreated US hepatitis patients: histologic improvement and hepatitis Be-antigen (HBeAg) seroconversion. Gastroenterology 114:A1235 (Abstract L0148).
6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA for the US Lamivudine Investigator Group. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1269.
7. Dienstag J, Lai CL, Hann HWL, et al. Natural history and lamivudine response in Asians versus Westerners with chronic hepatitis B. Gastroenterology (in press).
8. Gaeta GB, Nardiello S, Pizzella T, Russo G, Maisto A, Sardaro C, Galanti B, Giusti G. 1995. Semiquantitative anti-HBc IgM detection in children with chronic hepatitis B: a long-term follow-up study. J Med Virol 46:173-177.
9. Gitlin N. 1997. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 43:1500-1506.
10. Goodman Z, Dhillon AP, Wu PC, Gray F, Atkins M, Stevenson C, Barber J, Brown N, Crowther L, Woessner M. 1999. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 30:59 (Abstract GS5/26).
11. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215 (published erratum appears in Lancet 1997;349: 364).
12. Hassanein T, Colantoni A, de Maria N, van Thiel DH. 1996. Interferon-alpha 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. J Viral Hepatitis 3:333-340.
13. Heathcote J, Schalm SW, Cianciari J, Farrell G, Feinmann V, Shermann M, Dhillon AP, Moorat AE, Gray DF. 1998. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection. J Hepatol 28(Suppl 1):43 (Abstract GS2/07).
14. Hoofnagle JH. 1990. α-interferon therapy of chronic hepatitis B. Current status and recommendations. J Hepatol 11(Suppl):S100-S107.
15. Hoofnagle JH, Di Bisceglie AM. 1997. The treatment of chronic viral hepatitis. N Engl J Med 336:347-356.
16. Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. 1999. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 36:41-66.
17. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF, for the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
18. Leung N, Dienstag J, Schiff E, Sullivan M, Atkins M, Grice R, Woessner M, Brown N, Hunt CM. 1998. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients. Hepatology 28:587A (Abstract 1698).
19. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Wu PC, Dent JC, Edmundsen S, Liaw YF. 1999. Three year lamivudine therapy in chronic HBV. J Hepatol 30:59 (Abstract GS5/25).
20. Liaw YF, Lai CL, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Roman LC, Dent JC, Gray DF. 1998. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in Asia. Gastroenterology 114:A1289 (Abstract L0375).
21. Marines G, Smith HM, Naoumov NV, Williams R. 1994. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection. Hepatology 19:303-311.
22. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
23. Perrillo. 1994. The management of chronic hepatitis B. Am J Med 96(Suppl 1A):34S-40S.
24. Perillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish R, Villeneuve JP, Caldwell S, Brown N, Self P and the Lamivudine Transplant Group. 1997a. Long term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation. Hepatology 26:177A (Abstract 196).
25. Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish R, Dickson R, Adams P, Brown N, Self P, and the Lamivudine Transplant Group. 1997b. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT). Hepatology 26:260A (Abstract 526).
26. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF on behalf of an International Lamivudine Study Group. 2000. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46:562-568.
27. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, and the International Lamivudine Investigator Group. 1998a. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28:388A (Abstract 901).
28. Schiff E, Cianciara J, Kowdley K, Norkrans G, Perrillo R, Tong M, Crowther L, Wakeford J, Woessner M, Stevenson C, Brown N, and the International Lamivudine Investigator Group. 1998b. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. Hepatology 28:163A (Abstract 1).
29. Sponseller CA, Smith-Wilkaitis N, Bacon BR, Di Bisceglie AM. 1998. Clinical improvement in patients with decompensated liver disease due to hepatitis B following treatment with lamivudine. Hepatology 28:589A (Abstract 1708).
30. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF, and the Lamivudine Precore Mutant Study Group. 1999a. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
31. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Gray DF, Barber J, Hawley S. 1999b. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. Br J Hepatol 30(Suppl. 1):117 (Abstract P/C06/015).
32. Vail BA. 1997. Management of chronic viral hepatitis. Am J Family Phys 55:2749-2756.
33. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, Faruki H. 1997. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepato-Gastroenterology 44:808-812.
34. Villeneuve JP, Bilodeau M, Fenyves D, Pomier G, Pilon D, Raymond G, Willems W. 1997. Suppression of hepatitis B virus replication by lamivudine results in improvement of liver function in patients with severe cirrhosis. Hepatology 26:430A (Abstract 1205).
35. Yao GB. Management of hepatitis B in China. J Med Virol (in press).
36. Yao G, Wang B, Cui Z, Yao J, Minde Z. 1999. Long-term efficacy of lamivudine in the treatment of patients with chronic hepatitis B virus infection - a multicenter, randomised double-blind, placebo-controlled trial. Gastroenterology 116:A848 (Abstract G3688).
37. Zuckerman A. 1997. Hepatitis B in the Asian-Pacific region. Volume 1: screening, diagnosis and control. London: Royal College of Physicians.